| PROMOTER HYPERMETHYLATION OF p16 GENE AND DAPK GENE IN SERA FROM HEPATOCELLULAR CARCINOMA （HCC） PATIENTS |
| |
| 引用本文： | 林勍,陈龙邦,唐永明,王晶.PROMOTER HYPERMETHYLATION OF p16 GENE AND DAPK GENE IN SERA FROM HEPATOCELLULAR CARCINOMA （HCC） PATIENTS[J].中国癌症研究,2005,17(4):250-254. |
| |
| 作者姓名： | 林勍 陈龙邦 唐永明 王晶 |
| |
| 作者单位： | [1]Department of Medical Oncology, General Hospital of Nanjing Command ofPLA, Nanjing 210002 [2]Laboratory of Clinical Immunology, 454 Hospital of Nanjing Command ofPLA, Nanjing 210002 |
| |
| 摘 要： | Objective： To analyze the aberrant methylation of p16 gene and DAPK gene in sera from primary liver cancer patients ad to evaluate the clinical significance. Methods： A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene and DAPK gene in blood DNA from 64 cases of HCC patients, and to analyze the relation of the aberrant methylation of p16 gene and KAPK gene and the clinical pathological data. Results： 76.6%（49/64） of the sera from 64 cases of HCC patients showed hypermethylation for p16 promoter and 40.6% （26/64） for KAPK promoter, whereas no methylated p16 gene promoter and DAPK gene promoter were found in sera from benign liver diseases patients and normal control. Methylated p16 gene and KAPK gene promoters in sera did not strongly correlated with HBsAg, stage, metastasis and differentiation in HCC; but strongly correlated with AFP. Conclusion： Detection of the aberrant methylation of p16 gene and KAPK gene in blood DNA from HCC patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy.
|
| 关 键 词： | 启动子 p16基因 肝细胞癌 病理机制 |
| 文章编号： | 1000-9604（2005）04-0250-05 |
| 收稿时间： | 2005-09-02 |
| 修稿时间： | 2005-09-12 |
Promoter hypermethylation of p16 gene and DAPK gene in sera from hepatocellular carcinoma (HCC) patients |
| |
| Lin?Qing,Chen?Long-bang?Email author,Tang?Yong-ming,Wang?Jing.Promoter hypermethylation of p16 gene and DAPK gene in sera from hepatocellular carcinoma (HCC) patients[J].Chinese Journal of Cancer Research,2005,17(4):250-254. |
| |
| Authors: | Lin?Qing Email author" target="_blank">Chen?Long-bang?Email author Tang?Yong-ming Wang?Jing |
| |
| Institution: | (1) Department of Medical Oncology, General Hospital of Nanjing Command of PLA, 210002 Nanjing;(2) Laboratory of Clinical Immunology, 454 Hospital of Nanjing Command of PLA, 210002 Nanjing |
| |
| Abstract: | Objective: To analyze the aberrant methylation of p16 gene and DAPK gene in sera from primary liver cancer patients ad to evaluate the clinical significance. Methods: A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene and DAPK gene in blood DNA from 64 cases of HCC patients, and to analyze the relation of the aberrant methylation of p16 gene and KAPK gene and the clinical pathological data. Results: 76.6%(49/64) of the sera from 64 cases of HCC patients showed hypermethylation for p16 promoter and 40.6% (26/64) for KAPK promoter, whereas no methylated p16 gene promoter and DAPK gene promoter were found in sera from benign liver diseases patients and normal control. Methylated p16 gene and KAPK gene promoters in sera did not strongly correlated with HBsAg, stage, metastasis and differentiation in HCC; but strongly correlated with AFP. Conclusion: Detection of the aberrant methylation of p16 gene and KAPK gene in blood DNA from HCC patients might offer an effective means for the earlier auxiliary diagnosis of the malignancy. |
| |
| Keywords: | HCC p16 gene DAPK gene Serum DNA methylation |
| 本文献已被 CNKI 维普 万方数据 SpringerLink 等数据库收录！ |
